Robert Hills

Professor of Medical Statistics

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Hills is a Professor of Medical Statistics at the University of Oxford, UK. His research primarily focuses on acute myeloid leukaemia and cancer treatment methodologies, evidenced by his recent publications on topics such as cytosine arabinoside therapies and prognostic factors in colorectal cancer. Additionally, he examines the implications of treatment strategies and outcomes in older patients with leukemia, contributing significantly to the understanding of cancer treatment effects.

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (4)

Mhairi Copland

Professor of Translational Haematology

University of Glasgow

UNITED KINGDOM

View details

Jeremy Braybrooke

Honorary Associate Professor

University of Bristol

UNITED KINGDOM

View details

Frederik Damm

Charité - Universitätsmedizin Berlin

GERMANY

View details

Nicolas Duployez

Assistant Professor

Université de Lille

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Hills

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Seeing something new or with new eyes?

Prognostic impact of CEBPA mutational subgroups in adult AML

A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial

Benefits and risks of anthracyclines in early-stage breast cancer – Authors' reply

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit from Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients

Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

What drives CAR‐T emergent cytopenia?

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial

Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?

Gemtuzumab ozogamicin in (KMT2A)‐rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials

Therapy for isocitrate dehydrogenase 2 (IDH2)R172‐mutant acute myeloid leukaemia

Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial

High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?

Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

Collaborators (4)

Mhairi Copland

Jeremy Braybrooke

Frederik Damm

Nicolas Duployez

Make your next move.